✦ LIBER ✦
Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®)
✍ Scribed by C. L. BACON; E. SINGLETON; B. BRADY; B. WHITE; B. NOLAN; R. M. GILMORE; C. RYAN; C. KEOHANE; P. VINCE JENKINS; J. S. O’DONNELL
- Book ID
- 108775656
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 86 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1351-8216
No coin nor oath required. For personal study only.